Suggested remit: To appraise the clinical and cost effectiveness of bimatoprost slow-release biodegradable implant within its marketing authorisation for people with open angle glaucoma or ocular hypertension who are unsuitable for topical intraocular pressure lowering treatments
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6180

Email enquiries


Key events during the development of the guidance:

Date Update
21 July 2023 - 18 August 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6180
09 August 2023 Please note that following on from advice received from the company this appraisal has been scheduled to align with latest regulatory expectations. Therefore, the appraisal will begin in Q1 2024 when we will write to you about how you can get involved.
31 March 2023 In progress. DHSC referral received
15 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual